Sign In
Buy RARE
$22.41
+0.630 (+2.89%)
At Close: Jun 03, 2026
NEW YORK, Feb. 04, 2026 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi and Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired common stock of Ultragen
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Ultragenyx Pharmaceutical Inc. – RARE
02:08pm, Tuesday, 03'rd Feb 2026
NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). Such
Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome (MPS IIIA)
08:00am, Tuesday, 03'rd Feb 2026
Data represents up to 8.5 years of follow-up and are consistent across age, dose, and genotype BLA resubmitted to U.S. FDA in January 2026; Company expects up to six-month review period per FDA guidel
Ultragenyx Pharmaceutical Resubmits UX111 BLA for Sanfilippo Syndrome
12:05pm, Monday, 02'nd Feb 2026
RARE resubmits FDA filing for UX111 after CRL, adding long-term neurologic and biomarker data, with a Q3 2026 decision in sight.
Head-To-Head Survey: Nurix Therapeutics (NASDAQ:NRIX) vs. Ultragenyx Pharmaceutical (NASDAQ:RARE)
01:46am, Saturday, 31'st Jan 2026
Nurix Therapeutics (NASDAQ: NRIX - Get Free Report) and Ultragenyx Pharmaceutical (NASDAQ: RARE - Get Free Report) are both medical companies, but which is the better investment? We will compare the t
Company expects up to six-month review period per FDA guidelines New longer-term clinical data demonstrating durable positive brain biochemical and clinical effect for as long as 8.5 years to be pre
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
10:00am, Thursday, 29'th Jan 2026
NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE). Such investors a
Head to Head Comparison: Ultragenyx Pharmaceutical (NASDAQ:RARE) and Denali Therapeutics (NASDAQ:DNLI)
03:13am, Wednesday, 28'th Jan 2026
Ultragenyx Pharmaceutical (NASDAQ: RARE - Get Free Report) and Denali Therapeutics (NASDAQ: DNLI - Get Free Report) are both mid-cap medical companies, but which is the better investment? We will cont
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
01:28pm, Tuesday, 27'th Jan 2026
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). Such
Ongoing Ultragenyx Pharmaceutical Inc. (RARE) Investigation: Protect Your Rights - Contact Levi & Korsinsky
12:29am, Monday, 26'th Jan 2026
New York, New York--(Newsfile Corp. - January 26, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Ultragenyx Pharmaceutical Inc. ("Ultragenyx Pharmaceutical Inc
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 23'rd Jan 2026
NOVATO, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rar
Ultragenyx Stock Declines After Missing Primary Endpoints on its Phase III Orbit and Cosmic Studies
02:05pm, Friday, 23'rd Jan 2026
NEW YORK, Jan. 23, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE) following the Company's announcement of topline results from its Phase III
Tactical Resources Closes Financing
02:20pm, Thursday, 22'nd Jan 2026
THIS NEWS RELEASEIS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / January 22, 2026 / Tactical Resources Corp. (TSXV:RARE)(OTC P
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
10:00am, Thursday, 22'nd Jan 2026
NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE). Such investors a
Ultragenyx: From Bone To Brain, Capitulation Creates A Free Option On The Neuro Pipeline
06:01am, Thursday, 22'nd Jan 2026
Ultragenyx is rated BUY with a $55 price target, offering 145% implied upside after a sharp post-trial selloff. RARE's commercial base, anchored by Crysvita and Dojolvi, provides a robust revenue safe
